Dutch Health Tech Company Philips Faces Setback

The shares of Dutch health tech company Philips have experienced a significant decline in the European market. This comes after the U.S. drug regulator criticized the company’s handling of a major product recall, deeming it inadequate.

Stock Plummets in Response

At 10:45 a.m. London time, the stock listed on the Amsterdam exchange was trading 8% lower.

A Setback for Philips’ CEO

The recall of millions of ventilators used to treat sleep apnea has become the “highest priority” for Philips’ CEO, Roy Jakobs. The recent announcement by the U.S. Food and Drug Administration (FDA) further adds to the company’s challenges.

FDA Finds Testing and Analysis Inadequate

The FDA expressed its dissatisfaction with Philips’ testing and analysis of the recalled devices, stating that they are not adequate to fully evaluate the risks posed to users. The FDA believes additional testing is necessary and Philips has agreed to comply.

Philips’ Response

In response to the FDA’s concerns, Philips released a statement emphasizing their commitment to patient health and well-being. They will provide replacement devices and conduct further testing to ensure the safety of their sleep and respiratory care devices.

Shared Objective of Patient Safety

Philips acknowledges the shared objective with the FDA and other regulators to maintain the highest standards of patient safety and quality in healthcare delivery.